UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________

 

FORM 8-K

________________

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): April 21, 2005

 

ATHEROGENICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

8995 Westside Parkway

Alpharetta, GA  30004

(Address of principal executive offices)

 

Registrant's telephone number, including area code (678) 336-2500

_________________

      Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

      o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

      o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

      o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

      o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 2.02.  Results of Operations and Financial Condition.

 

            On April 21, 2005, AtheroGenics, Inc. issued a press release to report the company’s financial results for the first quarter ended March 31, 2005.  A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

 

Item 9.01.  Financial Statements and Exhibits.

 

The following exhibit is furnished as part of this current report on Form 8-K.

 

           

____________________

 

SIGNATURES

 

            Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

____________________

EXHIBIT INDEX